Background: This study aimed to compare the infection rate and infection-related mortality among all renal replacement therapies during the COVID-19 pandemics.
Methods: One thousand three hundred thirty-six end-stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID-19 infection and mortality rates were compared between patient groups.
Results: The COVID-19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID-19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID-19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (p < 0.001).
Conclusion: The COVID-19 infection rate and mortality were significantly lower than those of CHD in all home-based modalities subgroups.
Keywords: Covid-19; home-hemodialysis; mortality; renal replacement modality.
© 2022 International Society for Apheresis and Japanese Society for Apheresis.